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Abstract
Objective. Patients characterized with antinuclear antibodies (ANA) and disease symptoms 
related to one organ system can be described as having incomplete systemic lupus erythematosus 
(SLE). The aim of this multicentre study was to describe the outcome of these so-called 
incomplete SLE patients. Two aspects of the outcome were studied: (i) the disease course, defined
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by the presence or absence of clinical symptoms; and (ii) the number of patients that eventually 
developed full SLE.
Methods. Outcome parameters were the ACR criteria, the SLE disease Activity Index 
(SLEDAI), the European Consensus Lupus Activity Measure (ECLAM) and the requirement for 
treatment. In 10 European rheumatology centres, patients who had been evaluated in the last 
3 months of 1994 and had been diagnosed as having incomplete SLE on clinical grounds for 
at least 1 yr were included in the study. All 122 patients who were included in the study were 
evaluated annually during 3 yr of follow-up.
Results. Our results are confined to a patient cohort defined by disease duration of at least 
1 yr, being under clinical care at the different centres in Europe. These patients showed disease 
activity that was related mostly to symptoms of the skin and the musculoskeletal system, and 
leucocytopenia. During the follow-up, low doses of prednisolone were still being prescribed in 
43% of the patients. On recruitment to the study, 22 of the 122 incomplete SLE patients already 
fulfilled the ACR criteria for the diagnosis of SLE. In the 3 yr of follow-up only three patients 
developed SLE.
Conclusions. A high proportion of patients in our cohort defined on clinical grounds as having 
incomplete SLE eventually showed disease activity defined by the SLEDAI as well as ECLAM. 
However, only three cases developed to SLE during the follow-up. This suggests that incomplete 
SLE forms a subgroup of SLE that has a good prognosis.
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Patients often present with a constellation of disease 
features suggestive of systemic lupus erythematosus 
(SLE) but do not fulfil the classification criteria for 
SLE [1]. In the past, these patients have been described 
as having latent lupus [2], because only a minority 
of them eventually develop SLE. In recent studies of 
patients who do not fulfil the classification criteria for 
rheumatoid arthritis (RA), SLE, systemic sclerosis 
(SSC), Sjogren’s syndrome (SS), polydermatomyositis 
(PM) and/or mixed connective tissue disease (MCTD) 
[3-8], the terms ‘undifferentiated connective tissue 
disease’ (UCTD) and ‘early undifferentiated connective 
tissue disease’ have been suggested. Also, for patients 
diagnosed as having UCTD, a benign course of disease 
has been described with a low incidence of major 
complications, such as lung fibrosis, renal involvement 
and/or central nervous system involvement [9-12]. 
Recently, a study was performed evaluating the disease 
course of patients who had rheumatic symptoms and 
who also had antinuclear antibody (ANA) [13]. Only 
a minority of the patients in this study went on to 
develop SLE. Diagnosis of SLE is usually not difficult 
when all the characteristic symptoms are present, 
but may be difficult when there are only one or a few 
symptoms. In such cases the diagnosis cannot be 
made at the onset of the disease, and the patients must 
be observed for a longer period, until new symptoms 
appear and the diagnosis can be made with confidence. 
At present, in daily practice the diagnosis of SLE is 
confirmed when the patient fulfils the American College 
of Rheumatology (ACR) criteria [1 ].
One drawback of the ACR criteria is the possibility 
that patients with clinical signs related to only one organ 
system, e.g. the skin (rashes, discoid lesions), together 
with the presence of ANA and a positive LE cell pre­
paration may fulfil the ACR criteria for SLE. However, 
it is important to know whether these patients will
develop full SLE. Patients with disease symptoms 
related to one organ system only, together with the 
presence of ANA, can be said to have incomplete 
SLE. In order to describe the course of this so-called 
incomplete SLE, an international follow-up study was 
started under the supervision of the European League 
Against Rheumatism (EULAR) Standing Committee on 
International Clinical Studies Including Therapeutic 
Trials (ESCISIT). In this prospective follow-up invest­
igation, patients with incomplete SLE were studied to 
investigate whether they were prone to the development 
of full SLE and whether they had a stable disease course.
Materials and methods
Ten rheumatology centres in Europe participated in 
this study. All members of the study group were asked 
to include in the study those patients who had the 
diagnosis of incomplete SLE. Incomplete SLE was 
defined as the presence of symptoms related to one 
organ system plus the presence of ANA; patients were 
excluded if they had any other well-known disease. 
Furthermore, the patient was included in the study only 
if the clinician suspected that the patient might 
eventually develop SLE. In total, 122 patients with the 
diagnosis of incomplete SLE were included. The patients 
were recruited during the last 3 months of 1994. Char­
acteristics of all 122 patients are shown in Table 1. The 
clinical data of the patients were recorded in database 
protocols, with special attention to the disease course 
in the past and the disease activity present at the time 
of inclusion in the study. To obtain an impression of 
disease activity at entry to the study, the SLE disease 
activity index (SLEDAI) [14] and the European Con­
sensus Lupus Activity Measure (ECLAM) [15] were 
used. Only those patients who did not fulfil the ACR 
classification criteria [1 ] were considered to have an
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incomplete form of SLE. In order to standardize the 
data entries, every item in the protocol was defined 
according to the Dictionary of Rheumatic Disease 
prepared by the Glossary Committee of the American 
College of Rheumatology [16]. Otherwise, definitions 
were based upon the information given in the most 
commonly used textbooks of internal medicine and 
rheumatology. When the recruitment of patients with 
subclinical SLE was complete, the patients were 
analysed for their eventual diagnosis of SLE and the 
number of ACR criteria they fulfilled. In contrast to 
the revised ARA criteria, the different ANAs were 
considered as a single criterion.
The disease course was evaluated annually for all 
patients, changes were recorded, and during the last 
3 months of 1995, 1996 and 1997 the disease activity 
was scored. The physician involved in the study 
obtained all relevant information from the patients. 
Each centre recruited at least five patients who fulfilled 
the defined clinical criteria. The data were entered into 
a protocol form at the start of the study and annually 
during the 3 yr of follow-up.




Average age at start of study (yr) 40 + 13
Mean disease duration [yr (range)] 4.5 (1-40)
Geographical distribution Number of patients Percentage
Western Europe 27 22
Central Europe 25 20
Southern Europe 22 18
Eastern Europe 48 39
Table 2A. Follow-up of patients with incomplete SLE (n = 122): 
number of ACR criteria fulfilled in relation to disease activity score 
during 1995-1997
Number of ARA
Year criteria fulfilled ECLAM SLEDAI
1995 2.8 + 1.4 2.7 + 2.46 3.01 + 3.4
1996 2.4 + 1.8 2.9 + 3.2 4.1 + 6.1
1997 1.8 + 1.6 2.3 + 2.4 3.5 + 5.9
Results
Clinical diagnosis o f incomplete SLE versus 
the ACR criteria
Of the 122 patients recruited in 1994, 22 were found to 
fulfil the ACR criteria for SLE at their first evaluation in 
1995 and were excluded from further follow-up. At the 
follow-up in 1996, two patients had developed SLE 
according to the ACR criteria, and at the 1997 follow-up 
one patient had done so.
Disease course o f patients with incomplete SLE
Table 2 shows the follow-up of all 122 patients. The 
differences in the average number of ACR criteria 
present illustrate the change in disease activity during 
the follow-up period, as do also the ECLAm  and 
SLEDAI scores. It is clear that patients who fulfilled 
four or more ACR criteria had greater disease activity, 
as measured by both disease activity scoring systems.
Follow-up o f skin and musculoskeletal system
The overall disease activity is shown for all 122 patients 
in Table 2. The table does not indicate which symptoms 
showed the most change over time. However, changes 
in specified clinical signs were recorded every year, 
enabling us to establish which symptom had the most 
effect on changes in disease activity scores.
Table 3 shows the follow-up data for all specific 
clinical signs for the 100 patients who did not fulfil 
the ACR criteria for SLE. As shown in this table, the 
different symptoms increased, decreased or remained 
stable during the follow-up period. Most patients had 
complaints of the joints and fatigue. It is remarkable 
that at the evaluation in 1995 the prevalence of arthritis 
was 15%, but in the two subsequent years it was 19 and 
13%. Hardly any change was noted in other clinical 
signs related to the skin and musculoskeletal system 
(not all are shown in the tables), and the frequencies of 
these signs were very low.
Follow-up o f the cardiovascular and haematopoietic 
systems
The prevalence of periods of pericarditis declined during 
the follow-up period from 4 to 0% of the patients. 
A considerable number of patients had Raynaud’s 
phenomenon (25%); during the follow-up there was 
very little change in its prevalence (data not shown). 
Arterial hypertension was noted in a small percentage of 
patients (5%).
Table 2B. Incomplete SLE: disease activity related to the number of ACR criteria fulfilled during the follow-up period 
No. of ACR criteria2 fulfilled < 4 No. of ACR criteria2 fulfilled >4
Year ECLAMb SLEDAIb ECLAMb SLEDAIb No. of patients fulfilling >4 ACR criteria
1995 2.1 + 2.3 2.6 + 4.5 4.4 + 2.3 4.3 + 4 22
1996 2.1 + 2 2.0 + 4.3 6.1 + 4.5 8.5 + 9 24
1997 1.7 + 2 2.4 + 4.5 5.6 + 2.2 9.9 + 8.9 25
aEach defined clinical sign present was calculated as a positive criterion. 
bValues are median + s.d.
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Table 3. Changes in occurrence of symptoms in 100 patients with incomplete SLE 
(A) Between 1995 and 1996
Clinical signs















Fever 5 8 1 1 0 6 3
Fatigue 30 20 12 1 2 5 17
Articular
Arthritis 15 19 7 1 0 11 7
Skin involvement
Malar rash 4 6 3 0 0 3 1
Generalized rash 1 2 0 0 0 2 1
Discoid rash 4 1 0 0 0 1 4
Pericarditis 4 2 0 1 0 1 3
New psychiatric manifestations
Seizures 1 2 0 0 0 2 1
Stroke 2 1 0 0 0 1 0
Psychosis 0 1 0 0 0 1 0
Renal manifestations
Proteinuria 4 4 1 0 0 3 3
Raised serum creat 1 0 0 0 0 0 1
Urinary casts 3 1 0 0 0 1 3
Haematuria 3 1 0 0 0 1 3
5 5 2 0 0 3 3
Haematological features
Non-haemolytic anaemia 10 11 4 0 0 7 6
Haemolytic anaemia 2 0 0 0 0 0 2
Leucopenia 36 29 18 1 2 8 15
Thrombocytopenia 8 4 3 0 0 1 5
(B) Between 1996 and 1997
1997
Symptom present Symptom absent
1996 Decrease in Increase in Newly (complete
Clinical signs Symptom present Total No change severity severity developed cessation)
General
Fever 8 3 0 2 0 1 8
Fatigue 20 32 13 1 1 17 5
Articular
Arthritis 19 13 4 0 0 9 15
Skin involvement
Malar rash 6 10 1 0 0 9 5
Generalized rash 2 1 0 0 0 1 2
Discoid rash 1 4 1 0 0 3 0
Pericarditis 2 0 0 0 0 0 2
New psychiatric manifestations
Seizures 2 1 0 0 0 1 2
Stroke 3 1 0 0 1 0 2
Psychosis 1 2 0 0 0 2 1
Renal manifestations
Proteinuria 4 3 2 0 0 1 2
Raised serum creat 1 0 0 0 0 0 1
Urinary casts 5 8 1 0 0 7 4
Haematuria 5 0 0 0 0 0 0
Haematological features
Non-haemolytic anaemia 11 16 4 0 1 11 0
Haemolytic anaemia 0 0 0 0 0 0 0
Leucopenia 29 20 11 4 0 5 14
Thrombocytopenia 4 5 2 1 1 1 4
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Follow-up o f the renal and central nervous systems
Only a minority of the patients had symptoms related to 
renal involvement. Renal involvement was noted in at 
least 11% of our patients, haematuria in eight and 
proteinuria in four. As expected, very little involvement 
of the central nervous system was noted.
Follow-up o f haematological features
An episode of haemolytic anaemia was observed in 
two patients, but non-haemolytic anaemia was seen 
in 10 patients in 1995 and in 16 in 1997. The most 
frequently observed symptom was leucocytopenia, the 
prevalence of which ranged from 36% in 1995 to 20% 
in 1997.
Change in treatment during follow-up
At the time of recruitment to the study, 38% of the 
patients were being treated with prednisolone, none of 
them with a dose higher than 10 mg/day. Corresponding 
figures for the follow-up evaluations were 38, 43 and 
27%. Antimalarials were prescribed in 17% of the 
patients; during the follow-up this increased to 32%. 
Azathioprine was prescribed in only 2% of the patients 
in 1995, and in 3, 5 and 4.5% of patients at the 
subsequent follow-up evaluations.
Discussion
In daily practice, the diagnosis of SLE is made when the 
patient fulfils the ACR criteria. When these criteria are 
used, it can happen that the diagnosis SLE is considered 
in patients with symptoms related only to skin involve­
ment, such as malar rash and photosensitivity, which are 
further characterized by a positive LE test result and the 
presence of ANA. These two sets of clinical features— 
malar rash and photosensitivity plus a positive LE 
cell test, combined with positivity for ANA—are closely 
interrelated. The aim of this study was to investigate the 
clinical course of patients with incomplete SLE. When 
the patients were being recruited, the only criterion was 
that the clinician should have considered the diagnosis 
SLE but concluded that the criteria for full SLE were 
not met. It was our intention to analyse the disease 
course in these patients—in other words to confirm 
that these patients had a benign disease course—but 
also to try to define the diagnosis of incomplete SLE 
as opposed to SLE.
Patients with so-called latent lupus, or incomplete 
SLE, may represent a cohort of patients who will later 
develop SLE, or they may form a subset of SLE patients 
with mild disease. In one of the first studies [2], patients 
with latent lupus differed from SLE patients in general 
by the absence of involvement of the renal and central 
nervous systems. Overall, they were characterized by the 
presence of ANA, Raynaud’s phenomenon and/or 
arthritis and/or leucocytopenia and/or thrombopenia. 
These patients were similar to patients described by the 
term ‘undifferentiated’, which represents early disease 
that has not yet evolved into a disease such as SLE, 
scleroderma, SS or PM-DM. All these cohorts of
patients (latent lupus, UCTD, incomplete SLE) are 
characterized by non-specific symptoms such as 
arthralgia, Raynaud’s phenomenon, fatigue and auto­
antibodies to nuclear antigens [10].
In a recent study [13] it was shown that, among 
patients with both rheumatic complaints and ANA, 
only 16%—the diagnosis of SLE could be established 
within 3 yr of disease onset. Similar results have been 
described in patients not fulfilling the ACR criteria 
for SLE or other connective tissue disease 2 yr after the 
onset of disease symptoms [17]. These results suggest 
that ANA-positive patients with skin and/or musculo­
skeletal symptoms do not generally develop SLE. Others 
report similar findings [18, 19]. It remains very difficult 
to characterize these ANA-positive individuals who 
do not develop SLE. Only 22 of the 122 patients 
with incomplete SLE in our study fulfilled the ACR 
criteria at the first evaluation after recruitment. Of the 
remaining 100 patients, only three showed a change 
during follow-up, in that they developed SLE according 
to the ACR criteria. Table 3 illustrates the differences 
between the patients who fulfilled three or more ACR 
criteria. Patients fulfilling four or more ACR criteria 
were characterized by higher disease activity scores 
(SLEDAI, ECLAM). By analysing the defined clinical 
symptoms, two observations can be made. Over the years 
of follow-up, the disease activity showed a remitting 
course in individual patients. For example, if a patient 
had malar rash, the prevalence was 4-10%. These figures 
suggest that malar rash was observed for the first time in 
seven patients. However, this conclusion is not correct, 
because this symptom could have been present in the 
past but not when the patient was recruited into 
the study. The clinical signs were recorded only when 
they were present at the time of recruitment and once 
a year during follow-up. Attention was only paid to the 
changes that occurred. The tables show only the disease 
course, i.e. the changes in symptoms. When the patients 
were recruited they were characterized only by their 
history, not by their disease activity. When the preval­
ences of the clinical symptoms are considered, the dis­
crepancy between the skin-related symptoms in contrast 
to the haematological aberrations is obvious. Every 
characteristic symptom of the skin corresponds to a 
positive ACR criterion, whereas the haematological 
symptoms are frequently observed together. However, 
our study still shows that during the 3-yr follow-up our 
patients showed stable disease in that only a minority 
(three) of these patients later developed full SLE. At the 
time of recruitment into the study, one of these patients 
had skin involvement and two had haematological 
symptoms. A survey of the literature indicates that 
8-13% of patients with so-called UCTD will develop 
SLE after 3-5 yr [9, 11, 12]. The difference between this 
figure and our observation of 3% is related to the fact 
that our patients were known to have had incomplete 
SLE for between 3 % and 4 % yr, whereas the patients in 
the studies cited above had disease of more or less recent 
onset (overall up to 2 yr).
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Our study has shown clearly that although patients 
with so-called incomplete SLE may have periods of 
disease activity, only a small minority will develop full 
SLE. At the onset of their disease, the patients who 
later developed full SLE could not be differentiated 
from the patients with an incomplete disease course. 
It is not clear what factors determine whether incomplete 
SLE remains incomplete or develops into full SLE.
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